Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02650401 | Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options(STARTRK-NG) | active not recruiting | Phase 1 / Phase 2 | 69 | Hoffmann-La RocheINDUSTRY | 9 | Sep 23, 2026 | clinicaltrials |
| NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | recruiting | Phase 1 | 300 | National Cancer Institute (NCI)NIH |
| 2 |
| Sep 23, 2026 |
| clinicaltrials |
| NCT04222413 | Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors | recruiting | Phase 1 | 116 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06088004 | Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 218 | Suzhou Abogen Biosciences Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06253520 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | active not recruiting | Phase 1 | 210 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06302621 | Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | recruiting | Phase 1 | 32 | Massachusetts General HospitalOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06619587 | A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 410 | Genentech, Inc.INDUSTRY | 11 | Sep 23, 2026 | clinicaltrials |
| NCT06915753 | Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations(SURF431) | recruiting | Phase 1 | 125 | Tyra Biosciences, IncINDUSTRY | 4 | Sep 23, 2026 | clinicaltrials |
| NCT07136142 | A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07537881 | A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors | recruiting | Phase 1 / Phase 2 | 326 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07800936 | HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors | recruiting | Phase 1 | 44 | Parr Biotechnology (Hebei) Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07836036 | Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations | not yet recruiting | Phase 1 | 200 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03366116 | 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors | recruiting | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04855656 | Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors(MYTHIC) | recruiting | Phase 1 | 464 | Debiopharm International SAINDUSTRY | 5 | Sep 22, 2026 | clinicaltrials |
| NCT06641908 | Anti-GD2 ADC M3554 in Advanced Solid Tumors | recruiting | Phase 1 | 65 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT06771219 | SLV-154 Treatment of Advanced Cancers | recruiting | Phase 1 | 250 | Solve TherapeuticsINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07228247 | A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 147 | HutchmedINDUSTRY | 2 | Sep 22, 2026 | clinicaltrials |
| NCT07262619 | EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors | recruiting | Phase 1 / Phase 2 | 160 | Eikon TherapeuticsINDUSTRY | 14 | Sep 22, 2026 | clinicaltrials |
| NCT07545356 | A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 76 | Kivu Bioscience Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07682870 | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 42 | Virogin Biotech Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07763652 | A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07772934 | VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 260 | VelaVigo Bio IncINDUSTRY | 2 | Sep 22, 2026 | clinicaltrials |
| NCT07830667 | A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat | not yet recruiting | Phase 1 / Phase 2 | 79 | Children's Oncology GroupNETWORK | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07833735 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 400 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07834359 | A Study of HS-20197 in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 595 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05259709 | A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab | recruiting | Phase 1 | 50 | Regeneron PharmaceuticalsINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06005740 | A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer | active not recruiting | Phase 1 | 70 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT06169579 | An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers | enrolling by invitation | Phase 1 | 96 | Shenzhen NewDEL Biotech, Co., LtdINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06260514 | Study of APR-1051 in Patients With Advanced Solid Tumors(ACESOT-1051) | recruiting | Phase 1 | 90 | Aprea TherapeuticsINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06717750 | A Study of CSCJC3456 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 102 | Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06736379 | Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer | recruiting | Phase 1 | 41 | VLP TherapeuticsINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07629960 | A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations | recruiting | Phase 1 / Phase 2 | 265 | Blueprint Medicines CorporationINDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT07744152 | A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours) | recruiting | Phase 1 | 137 | Boehringer IngelheimINDUSTRY | 5 | Sep 21, 2026 | clinicaltrials |
| NCT07830199 | A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics | not yet recruiting | Phase 1 | 208 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04693468 | Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial | recruiting | Phase 1 | 111 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05267626 | Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 159 | Aulos Bioscience, Inc.INDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT06088472 | TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors | active not recruiting | Phase 1 | 12 | Grit BiotechnologyINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06398418 | R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors | recruiting | Phase 1 | 33 | Rise Therapeutics LLCINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06563375 | Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors | recruiting | Phase 1 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06859762 | A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 630 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07159126 | A Study of DS3610a in Participants With Advanced Solid Tumor | recruiting | Phase 1 | 70 | Daiichi SankyoINDUSTRY | 3 | Sep 18, 2026 | clinicaltrials |
| NCT07396584 | HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor | recruiting | Phase 1 / Phase 2 | 186 | HutchmedINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07435038 | Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 120 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07667842 | Study of D3L-002 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 24 | D3 Bio (Wuxi) Co., LtdINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07827144 | A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours) | not yet recruiting | Phase 1 | 90 | AIMEDBIOOTHER_GOV | 5 | Sep 18, 2026 | clinicaltrials |
| NCT04998422 | A Study of HG381 Administered to Patients With Advanced Solid Tumors | recruiting | Phase 1 | 57 | HitGen Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05007782 | Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors | active not recruiting | Phase 1 | 304 | Gilead SciencesINDUSTRY | 5 | Sep 17, 2026 | clinicaltrials |
| NCT06605222 | A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 201 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06953323 | A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 86 | Wigen Biomedicine Technology (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | recruiting | Phase 1 / Phase 2 | 205 | Terremoto Biosciences Inc.INDUSTRY | 4 | Sep 17, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials